Clarius Group LLC’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $621K | Sell |
11,510
-1,027
| -8% | -$49.4K | 0.04% | 173 |
|
|
2025
Q3 | $565K | Sell |
12,537
-12,072
| -49% | -$564K | 0.03% | 193 |
|
|
2025
Q2 | $1.14M | Buy |
24,609
+5,073
| +26% | +$249K | 0.07% | 134 |
|
|
2025
Q1 | $1.19M | Buy |
19,536
+3,995
| +26% | +$233K | 0.07% | 124 |
|
|
2024
Q4 | $879K | Buy |
15,541
+1,409
| +10% | +$78.7K | 0.06% | 136 |
|
|
2024
Q3 | $713K | Sell |
14,132
-2,103
| -13% | -$98.7K | 0.05% | 158 |
|
|
2024
Q2 | $674K | Buy |
16,235
+8,061
| +99% | +$361K | 0.05% | 174 |
|
|
2024
Q1 | $443K | Sell |
8,174
-4,691
| -36% | -$239K | 0.03% | 247 |
|
|
2023
Q4 | $660K | Sell |
12,865
-3,293
| -20% | -$173K | 0.05% | 192 |
|
|
2023
Q3 | $938K | Sell |
16,158
-6,301
| -28% | -$386K | 0.09% | 122 |
|
|
2023
Q2 | $1.79M | Buy |
22,459
+917
| +4% | +$61.5K | 0.14% | 80 |
|
|
2023
Q1 | $1.47M | Sell |
21,542
-968
| -4% | -$68.3K | 0.12% | 94 |
|
|
2022
Q4 | $1.97M | Buy |
22,510
+2,159
| +11% | +$163K | 0.18% | 76 |
|
|
2022
Q3 | $1.45M | Buy |
20,351
+451
| +2% | +$32.7K | 0.14% | 85 |
|
|
2022
Q2 | $1.53M | Buy |
19,900
+811
| +4% | +$61.8K | 0.15% | 89 |
|
|
2022
Q1 | $1.19M | Hold |
19,089
| – | – | 0.09% | 116 |
|
|
2021
Q4 | $1.19M | Sell |
19,089
-4,154
| -18% | -$244K | 0.09% | 116 |
|
|
2021
Q3 | $1.38M | Sell |
23,243
-170
| -0.7% | -$11.2K | 0.12% | 93 |
|
|
2021
Q2 | $1.56M | Buy |
23,413
+398
| +2% | +$26K | 0.14% | 88 |
|
|
2021
Q1 | $1.45M | Buy |
23,015
+2,175
| +10% | +$135K | 0.14% | 89 |
|
|
2020
Q4 | $1.29M | Buy |
20,840
+1,822
| +10% | +$112K | 0.14% | 82 |
|
|
2020
Q3 | $1.15M | Sell |
19,018
-370
| -2% | -$22.3K | 0.15% | 75 |
|
|
2020
Q2 | $1.14M | Buy |
19,388
+2,342
| +14% | +$140K | 0.16% | 72 |
|
|
2020
Q1 | $950K | Buy |
17,046
+1,638
| +11% | +$100K | 0.18% | 66 |
|
|
2019
Q4 | $1.03M | Buy |
15,408
+5,547
| +56% | +$318K | 0.16% | 73 |
|
|
2019
Q3 | $500K | Buy |
9,861
+1,917
| +24% | +$90.1K | 0.09% | 118 |
|
|
2019
Q2 | $360K | Buy |
7,944
+773
| +11% | +$36K | 0.07% | 142 |
|
|
2019
Q1 | $342K | Buy |
7,171
+3,310
| +86% | +$165K | 0.08% | 126 |
|
|
2018
Q4 | $201K | Buy |
3,861
+178
| +5% | +$9.56K | 0.07% | 117 |
|
|
2018
Q3 | $229K | Buy |
+3,683
| New | +$219K | 0.08% | 111 |
|
|
2017
Q1 | – | Sell |
-4,413
| Closed | -$257K | – | 92 |
|
|
2016
Q4 | $257K | Buy |
4,413
+344
| +8% | +$18.8K | 0.11% | 76 |
|
|
2016
Q3 | $217K | Sell |
4,069
-1,881
| -32% | -$121K | 0.1% | 85 |
|
|
2016
Q2 | $438K | Buy |
5,950
+2,500
| +72% | +$177K | 0.23% | 52 |
|
|
2016
Q1 | $220K | Sell |
3,450
-1,424
| -29% | -$89.8K | 0.12% | 77 |
|
|
2015
Q4 | $335K | Buy |
+4,874
| New | +$322K | 0.19% | 52 |
|
Other funds holding BMY
Clarius Group LLC's BMY Position: Q4 2025 in Review
Clarius Group LLC reduced its Bristol-Myers Squibb (BMY) stake by 8.2% in Q4 2025, selling an estimated $49.4K and leaving 11,510 shares worth $621K. The position accounts for 0.04% of the portfolio, ranked #173.
Clarius Group LLC first reported a position in BMY in Q4 2015 and has held it in 35 quarters since. The position peaked at $1.97M in Q4 2022. 2,448 funds tracked by Wall St. Rank hold BMY as of Q4 2025.
- Clarius Group LLC held 11,510 shares of Bristol-Myers Squibb worth $621K as of Q4 2025.
- Clarius Group LLC sold 1,027 Bristol-Myers Squibb shares in Q4 2025, an estimated $49.4K.
- Bristol-Myers Squibb made up 0.04% of Clarius Group LLC's portfolio in Q4 2025, its #173 holding.
- Clarius Group LLC first reported a position in Bristol-Myers Squibb in Q4 2015 and has held it in 35 quarters since.
- Clarius Group LLC's Bristol-Myers Squibb position peaked at $1.97M in Q4 2022.
- 2,448 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.
Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.